Treatment of advanced neuroendocrine tumors with ~(90)Y-DOTATATE
10.3760/cma.j.issn.0253-9780.2010.01.001
- VernacularTitle:~(90)Y-DOTATATE治疗进展期神经内分泌肿瘤的临床价值
- Author:
Yong-hui, CHEN
;
Fang, LI
;
Bing, JIA
;
Hong-li, JING
;
Li-bo, CHEN
;
Fang, CHEN
;
Fan, WANG
;
Yan-tong, DU
;
Yan-ru, MA
;
Meng, OUYANG
;
Yan-song, LIN
;
Zeng-shou, KANG
- Publication Type:Journal Article
- Keywords:
Neuroendocrine tumors;
Yttrium radioisotopes;
Radiotherapy;
DOTATATE
- From:Chinese Journal of Nuclear Medicine
2010;30(1):1-4
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effcacy and side effects of [~(90)Y-1,4,7,10-tetraazacyclododecane-N,N',N",N'"-tetraacetic acid (DOTA)~0,Tyr3]octreotate (~(90)Y-DOTATATE) combined with lysine as a renal protective agent.Methods Twenty-five patients with advanced neuroendocrine tumors were confirmed as somatostatin receptor subtype-2 (SSTR2)-positive by somatostatin receptor scintigraphy (SRS).Each patient received 1-5 cycles of treatment and the interval between two cycles of treatment was 6-9 weeks.~(90)Y-DOTATATE was administered intravenously within 30 min.Lysine was injected before and after the administration of ~(90)Y-DOTATATE.After each treatment cycle.the side effects were assessed according to National Cancer Institute Grading Criteria(NCIGC).The etticacy was evaluated by the WHO criteria 8 weeks after the last treatment.Results Pattial remission was found in 1 patient (4%).minor response in 3 patients(12%),stable disease in 16 patients (64%)and tumor progression in 5 patients (20%).Two patients suffered from renal functional injuries and 3 patients developed leukocytopenia.Three patients showed nausea while another 3 patients presented vomiting.Conclusions ~(90)Y-DOTATATE in association with lysine may be a promising treatment method for the patients with metastatic and inoperable neuroendocrine tumors.More research work may be directed to reduce renal injury.
